Yue Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yue Zeng has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
Binqiang Xu
Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
11 shared publicationsQixiang Mei
Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
11 shared publicationsYang Fu
Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
11 shared publicationsNuoming Yin
Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
10 shared publicationsWenfei Qin
School of Health Science and Engineering, Shanghai Engineering Research Center of Food Microbiology, University of Shanghai for Science and Technology, Shanghai, China
8 shared publications- Chunlan Huang
Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Springer Nature in Microbiome
- Vol. 14 (1)
Gut microbiota-derived riboflavin mediates protective effects of MUC2 in acute pancreatitis via CD40-macrophage pathway
Gut barrier dysfunction is critical in the pathogenesis of acute pancreatitis (AP), yet the underlying mechanisms remain unclear. Mucin 2 (MUC2), the prima
- 12 August 2026
- Published by Springer Nature in Microbiome
- Vol. 14 (1)
Open AccessGut microbiota-derived riboflavin mediates protective effects of MUC2 in acute pancreatitis via CD40-macrophage pathway
Gut barrier dysfunction is critical in the pathogenesis of acute pancreatitis (AP), yet the underlying mechanisms remain unclear. Mucin 2 (MUC2), the prima
- Open Access
- 6 August 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1850105
Effect of high-dose intravenous vitamin C on organ support-free days within the first 14 days in severe acute pancreatitis patients: a multicenter, randomized, double-blind, placebo-controlled clinical trial protocol
Background: The global incidence of severe acute pancreatitis (SAP) is increasing, yet mortality rates remain persistently high. Novel therapeutic approaches are urgently needed to improve outcomes. The aim of this study is to evaluate the efficacy of high-dose intravenous vitamin C in improving organ support-free days within the first 14 days and other clinical outcomes in patients with SAP. Method: This is a prospective, randomized, double-blind, multicenter clinical trial. Participants will be stratified and randomly assigned to either the HDIVC group or the control group. Data will be analyzed using SAS 9.4 with two-sided tests and a significance threshold of p < 0.05. This study will be conduct at eight hospitals in China, including Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai General Hospital, Changhai Hospital, Sichuan Provincial People’s Hospital, Chongqing Daping Hospital, The Second People’s Hospital of Chengdu, Guanghan People’s Hospital and Chongqing Emergency Medical Center. Eligible patients are adults (age ≥ 18 years) diagnosed with severe acute pancreatitis according to 2012 Atlanta classification within 7 days of onset. HDIVC (500 mg/kg, 2 g/h) or placebo (normal saline) will be administered via central vein for 7 days. The primary outcome is organ support-free days within the first 14 days. Secondary outcomes include ICU all-cause mortality, changes in inflammatory biomarkers, and organ failure scores. Discussion: If proven effective, the results of this trial could establish high-dose intravenous vitamin C as a cost-effective adjunctive therapy to improve survival in patients with severe acute pancreatitis and potentially inform future clinical practice guidelines. Clinical trial registration: ClinicalTrials.gov , identifier NCT06897384.
- 6 August 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1850105
Open AccessEffect of high-dose intravenous vitamin C on organ support-free days within the first 14 days in severe acute pancreatitis patients: a multicenter, randomized, double-blind, placebo-controlled clinical trial protocol
Background: The global incidence of severe acute pancreatitis (SAP) is increasing, yet mortality rates remain persistently high. Novel therapeutic approaches are urgently needed to improve outcomes. The aim of this study is to evaluate the efficacy of high-dose intravenous vitamin C in improving organ support-free days within the first 14 days and other clinical outcomes in patients with SAP. Method: This is a prospective, randomized, double-blind, multicenter clinical trial. Participants will be stratified and randomly assigned to either the HDIVC group or the control group. Data will be analyzed using SAS 9.4 with two-sided tests and a significance threshold of p < 0.05. This study will be conduct at eight hospitals in China, including Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai General Hospital, Changhai Hospital, Sichuan Provincial People’s Hospital, Chongqing Daping Hospital, The Second People’s Hospital of Chengdu, Guanghan People’s Hospital and Chongqing Emergency Medical Center. Eligible patients are adults (age ≥ 18 years) diagnosed with severe acute pancreatitis according to 2012 Atlanta classification within 7 days of onset. HDIVC (500 mg/kg, 2 g/h) or placebo (normal saline) will be administered via central vein for 7 days. The primary outcome is organ support-free days within the first 14 days. Secondary outcomes include ICU all-cause mortality, changes in inflammatory biomarkers, and organ failure scores. Discussion: If proven effective, the results of this trial could establish high-dose intravenous vitamin C as a cost-effective adjunctive therapy to improve survival in patients with severe acute pancreatitis and potentially inform future clinical practice guidelines. Clinical trial registration: ClinicalTrials.gov , identifier NCT06897384.
- Open Access
- 31 May 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
B3GNT7 preserves intestinal barrier integrity: a key defense mechanism against acute pancreatitis progression
Mucin-2 (MUC2) plays a crucial role in maintaining intestinal homeostasis during acute pancreatitis (AP). We aimed to investigate the role of B3GNT7 (β-1,3-N-acetylglucosamine transferase) in the O-glycosylation of MUC2 in AP. We used two mouse models of AP induced by caerulein/lipopolysaccharide or L-arginine, and observed colonic goblet cells using electron microscopy, noting that Golgi damage was linked to decreased levels of mature MUC2. Golgi stress–associated proteins (reduced GM130 and elevated GOLPH3) were identified using immunofluorescence. Transcriptome analysis revealed the downregulation of B3gnt7, a glycosyltransferase that is highly enriched in the Golgi apparatus of goblet cells in AP mice. B3GNT7 expression was negatively correlated with pancreatic and colonic pathological scores. In patients with AP, intestinal B3GNT7 levels are markedly reduced and correlated with Ranson scores, C-reactive protein levels, and intestinal permeability markers (serum diamine oxidase and D-lactate). Adeno-associated virus (AAV)-mediated knockdown of B3GNT7 reduced O-glycosylated MUC2 levels, exacerbated pancreatic and systemic inflammation, and worsened intestinal permeability and dysbiosis. In vitro, LPS-treated HT-29 cells exhibited Golgi stress (decreased levels of B3GNT7 and O-glycosylated MUC2) that was reversed by L-glutathione (GSH). These findings demonstrate that B3GNT7 downregulation, mediated by Golgi stress, disrupts MUC2 O-glycosylation, exacerbating AP by impairing intestinal homeostasis.
- 31 May 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
Open AccessB3GNT7 preserves intestinal barrier integrity: a key defense mechanism against acute pancreatitis progression
Mucin-2 (MUC2) plays a crucial role in maintaining intestinal homeostasis during acute pancreatitis (AP). We aimed to investigate the role of B3GNT7 (β-1,3-N-acetylglucosamine transferase) in the O-glycosylation of MUC2 in AP. We used two mouse models of AP induced by caerulein/lipopolysaccharide or L-arginine, and observed colonic goblet cells using electron microscopy, noting that Golgi damage was linked to decreased levels of mature MUC2. Golgi stress–associated proteins (reduced GM130 and elevated GOLPH3) were identified using immunofluorescence. Transcriptome analysis revealed the downregulation of B3gnt7, a glycosyltransferase that is highly enriched in the Golgi apparatus of goblet cells in AP mice. B3GNT7 expression was negatively correlated with pancreatic and colonic pathological scores. In patients with AP, intestinal B3GNT7 levels are markedly reduced and correlated with Ranson scores, C-reactive protein levels, and intestinal permeability markers (serum diamine oxidase and D-lactate). Adeno-associated virus (AAV)-mediated knockdown of B3GNT7 reduced O-glycosylated MUC2 levels, exacerbated pancreatic and systemic inflammation, and worsened intestinal permeability and dysbiosis. In vitro, LPS-treated HT-29 cells exhibited Golgi stress (decreased levels of B3GNT7 and O-glycosylated MUC2) that was reversed by L-glutathione (GSH). These findings demonstrate that B3GNT7 downregulation, mediated by Golgi stress, disrupts MUC2 O-glycosylation, exacerbating AP by impairing intestinal homeostasis.
- 8 May 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (9) , 4270-4281
The Increasing Disease Burden Among Males and the Elderly in Pancreatitis: Latest Insights from the 2021 Global Burden of Disease Study
To develop effective prevention measures, a deep understanding of the evolution patterns and trends of pancreatitis burden is essential. Our study aims to quantify the burden related to pancreatitis in 204 countries and regions from 1990 to 2021. Data related to pancreatitis were derived from the Global Burden of Disease Study in 2021. The burden of pancreatitis was assessed using incidence, disability-adjusted life years (DALYs), deaths and their corresponding age-standardized rates (ASRs), stratified by age, sex, Sociodemographic Index (SDI) and Human Development Index (HDI). The estimated annual percentage change was used to quantify the variation in ASRs. The analysis covered the period from 1990 to 2021. In 2021, there were 2,741,736 new cases of pancreatitis (95% UI 2,413,878-3,133,076), leading to 122,416 deaths (95% UI 109,848-141,362), accounting for 0.22% of global deaths, causing a loss of 4,101,154 DALYs (95% UI 3,647,631-4,684,283). The burden of pancreatitis in 2021 and its trends from 1990 to 2021 showed substantial differences based on sex, SDI quintiles and geographical regions. Based on our results, the burden of pancreatitis is high and increasing among males and the elderly. Countries with high levels of SDI bear a greater disease burden. Forecast analysis predicts that by 2050, the number of deaths and DALYs related to pancreatitis will continue to rise. Understanding the disease burden and future burden trends associated with pancreatitis is crucial for implementing effective interventions to alleviate the global burden.
- 8 May 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (9) , 4270-4281
The Increasing Disease Burden Among Males and the Elderly in Pancreatitis: Latest Insights from the 2021 Global Burden of Disease Study
To develop effective prevention measures, a deep understanding of the evolution patterns and trends of pancreatitis burden is essential. Our study aims to quantify the burden related to pancreatitis in 204 countries and regions from 1990 to 2021. Data related to pancreatitis were derived from the Global Burden of Disease Study in 2021. The burden of pancreatitis was assessed using incidence, disability-adjusted life years (DALYs), deaths and their corresponding age-standardized rates (ASRs), stratified by age, sex, Sociodemographic Index (SDI) and Human Development Index (HDI). The estimated annual percentage change was used to quantify the variation in ASRs. The analysis covered the period from 1990 to 2021. In 2021, there were 2,741,736 new cases of pancreatitis (95% UI 2,413,878-3,133,076), leading to 122,416 deaths (95% UI 109,848-141,362), accounting for 0.22% of global deaths, causing a loss of 4,101,154 DALYs (95% UI 3,647,631-4,684,283). The burden of pancreatitis in 2021 and its trends from 1990 to 2021 showed substantial differences based on sex, SDI quintiles and geographical regions. Based on our results, the burden of pancreatitis is high and increasing among males and the elderly. Countries with high levels of SDI bear a greater disease burden. Forecast analysis predicts that by 2050, the number of deaths and DALYs related to pancreatitis will continue to rise. Understanding the disease burden and future burden trends associated with pancreatitis is crucial for implementing effective interventions to alleviate the global burden.
- Open Access
- 21 January 2026
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 20 (5) , 101732
Blautia coccoides Alleviates Acute Pancreatitis via Bile Salt Hydrolase-mediated Deoxycholic Acid Production and Farnesoid X Receptor Signaling
- 21 January 2026
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 20 (5) , 101732
Open AccessBlautia coccoides Alleviates Acute Pancreatitis via Bile Salt Hydrolase-mediated Deoxycholic Acid Production and Farnesoid X Receptor Signaling
- Open Access
- 1 January 2026
- Published by Tsinghua University Press in Food Science and Human Wellness
- Vol. 15 (1) , 9250861
Caffeine as a microbiome modulator: a novel therapeutic strategy for hypertriglyceridemia-related acute pancreatitis
Hypertriglyceridemia (HTG) is a common and significant contributor to acute pancreatitis (AP). Caffeine has been reported to have a protective effect against pancreatic disorders. However, the role of caffeine in hypertriglyceridemia acute pancreatitis (HAP) is still unknown. To investigate a new understanding of the relationship between caffeine and gut microbiota in HAP development. Using multi-omics analysis of 71 HAP and HTG patients, their characteristics of intestinal microecology were detected. HTG mice models were established through either pharmacological induction (P-407 intraperitoneal injection) or genetic ablation of GPIHBP1 (GPIHBP1−/−). Genes deferentially expressed in the gut were identified by RNA sequencing and the role of caffeine in reshaping gut microbial networks was investigated. Caffeine levels decreased significantly in HAP patients and were inversely correlated with the severity of HAP. Caffeine maintained the intestinal homeostasis and attenuated HAP through a gut microbiota-dependent manner in the mouse model. Specially, the commensal Faecalibacterium prausnitzii, which contributed most in distinguishing the differences between HTG and HAP patients, has been found to be related to the effect of caffeine on alleviating HAP. RNA sequencing combined with TLR4−/− mice revealed that TLR4/NLRP3 may be the key signaling pathway for caffeine to maintain intestinal homeostasis and alleviating HAP. This study reveals the gut metabolites and microbiota characteristics of HAP and HTG patients, and explores the therapeutic potential of caffeine against HAP from the perspective of gut microbiota.
- 1 January 2026
- Published by Tsinghua University Press in Food Science and Human Wellness
- Vol. 15 (1) , 9250861
Open AccessCaffeine as a microbiome modulator: a novel therapeutic strategy for hypertriglyceridemia-related acute pancreatitis
Hypertriglyceridemia (HTG) is a common and significant contributor to acute pancreatitis (AP). Caffeine has been reported to have a protective effect against pancreatic disorders. However, the role of caffeine in hypertriglyceridemia acute pancreatitis (HAP) is still unknown. To investigate a new understanding of the relationship between caffeine and gut microbiota in HAP development. Using multi-omics analysis of 71 HAP and HTG patients, their characteristics of intestinal microecology were detected. HTG mice models were established through either pharmacological induction (P-407 intraperitoneal injection) or genetic ablation of GPIHBP1 (GPIHBP1−/−). Genes deferentially expressed in the gut were identified by RNA sequencing and the role of caffeine in reshaping gut microbial networks was investigated. Caffeine levels decreased significantly in HAP patients and were inversely correlated with the severity of HAP. Caffeine maintained the intestinal homeostasis and attenuated HAP through a gut microbiota-dependent manner in the mouse model. Specially, the commensal Faecalibacterium prausnitzii, which contributed most in distinguishing the differences between HTG and HAP patients, has been found to be related to the effect of caffeine on alleviating HAP. RNA sequencing combined with TLR4−/− mice revealed that TLR4/NLRP3 may be the key signaling pathway for caffeine to maintain intestinal homeostasis and alleviating HAP. This study reveals the gut metabolites and microbiota characteristics of HAP and HTG patients, and explores the therapeutic potential of caffeine against HAP from the perspective of gut microbiota.
- Open Access
- 21 November 2025
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 11 (1)
Faecalibacterium prausnitzii alleviates experimental recurrent acute pancreatitis by producing oleic acid to regulate MAPK/NF-κB signaling and Th17/Treg balance
Acute pancreatitis (AP) is a complex gastrointestinal disorder associated with disruptions in the gut microbiome. However, the gut microbial and metabolomic profiles in recurrent acute pancreatitis (RAP), which is a clinically distinct subtype of AP, remain unclear. This study integrated microbiome-metabolome analysis to identify the key gut microbial species and metabolic pathways associated with RAP. The findings reveal that the abundance of Faecalibacterium prausnitzii (Fp) is significantly diminished in RAP patients, exhibiting a strong negative correlation with disease severity. Consistent with this observation, fecal microbiota transplantation enriched with Fp significantly ameliorated pancreatic injury in RAP mice. We further isolated Fp Ai 3−16 strain from the stool of healthy volunteers. Functional validation using experimental AP models demonstrates that Fp Ai 3-16 and its metabolite oleic acid (OA) can effectively attenuate pancreatitis by modulating MAPK/NF-κB signaling pathways and restoring the intestinal Th17/Treg balance. Importantly, these results extend beyond the context of RAP, as they highlight the broader significance of the gut-pancreas axis in the pathogenesis of AP. Thus, the elucidation of the underlying molecular mechanisms offers novel therapeutic avenues for RAP management and provides a foundation for further investigations into the intricate interplay between the gut microbiome and the pancreas.
- 21 November 2025
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 11 (1)
Open AccessFaecalibacterium prausnitzii alleviates experimental recurrent acute pancreatitis by producing oleic acid to regulate MAPK/NF-κB signaling and Th17/Treg balance
Acute pancreatitis (AP) is a complex gastrointestinal disorder associated with disruptions in the gut microbiome. However, the gut microbial and metabolomic profiles in recurrent acute pancreatitis (RAP), which is a clinically distinct subtype of AP, remain unclear. This study integrated microbiome-metabolome analysis to identify the key gut microbial species and metabolic pathways associated with RAP. The findings reveal that the abundance of Faecalibacterium prausnitzii (Fp) is significantly diminished in RAP patients, exhibiting a strong negative correlation with disease severity. Consistent with this observation, fecal microbiota transplantation enriched with Fp significantly ameliorated pancreatic injury in RAP mice. We further isolated Fp Ai 3−16 strain from the stool of healthy volunteers. Functional validation using experimental AP models demonstrates that Fp Ai 3-16 and its metabolite oleic acid (OA) can effectively attenuate pancreatitis by modulating MAPK/NF-κB signaling pathways and restoring the intestinal Th17/Treg balance. Importantly, these results extend beyond the context of RAP, as they highlight the broader significance of the gut-pancreas axis in the pathogenesis of AP. Thus, the elucidation of the underlying molecular mechanisms offers novel therapeutic avenues for RAP management and provides a foundation for further investigations into the intricate interplay between the gut microbiome and the pancreas.
- Open Access
- 5 August 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 849-859
TSH as a novel biomarker for recurrence of hypertriglyceridemia pancreatitis: a clinical predictive tool linking lipid dysregulation to inflammation
- 5 August 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 849-859
Open AccessTSH as a novel biomarker for recurrence of hypertriglyceridemia pancreatitis: a clinical predictive tool linking lipid dysregulation to inflammation
- Open Access
- 15 July 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-22
Faecalibacterium prausnitzii enhances intestinal IgA response by host-microbe derived inecalcitol in colitis
Faecalibacterium prausnitzii plays a crucial role in ulcerative colitis (UC) remission, but its action mechanism is unknown. Here, we aimed to explore the potential mechanisms focusing on the interaction of F. prausnitzii with host immune response and its potential modulation on gut microbiome. RNA-seq analysis together with 16S rRNA sequencing and metabolomics were performed in a dextran sodium sulfate (DSS)-induced colitis mouse model followed by F. prausnitzii gavage. To present evidence of sIgA involved in the anti-inflammatory effects of F. prausnitzii, we further applied immunoglobulin A (IgA) knockout mice and secretory IgA (sIgA) depletion mouse models using polymeric immunoglobulin receptor (pIgR) neutralizing antibody. Colonic immune cells were characterized by flow cytometry. The fecal relative abundance of F. prausnitzii, inecalcitol, and colonic IgA expression were assessed in UC patients. F. prausnitzii markedly ameliorated colitis by alleviating intestinal inflammation and barrier dysfunction, with significantly decreased abundance of pro-inflammatory taxa (Enterococcus, Desulfovibrio, Escherichia-Shigella, and Enterorhabdus) and increased abundance of Lachnospiraceae NK4A136_group. Functions related to intestinal immune network for IgA production pathway were up-regulated shown by transcriptomics and KEGG pathway analysis. Increased expression of IgA production associated genes including MHCII-related genes, Aicda, and Tnfrsfl3c were verified, accompanied by up-regulated colonic IgA and pIgR. The IgA knockout mice and sIgA depletion model weakened the anti-inflammation and microbiota-modulation effects of F. prausnitzii, which was further proved by fecal microbiota transplantation (FMT). The shift profile of fecal metabolites after F. prausnitzii supplement was characterized by increased production of inecalcitol, which may account for the enhanced IgA response. In a cohort of UC patients, the relative abundance of F. prausnitzii was decreased and positively correlated with colonic IgA expression and negatively correlated with disease severity. F. prausnitzii effectively alleviated colonic inflammation and modulated dysbiosis via enhancing colonic IgA response, thus showing promise as a UC treatment.
- 15 July 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-22
Open AccessFaecalibacterium prausnitzii enhances intestinal IgA response by host-microbe derived inecalcitol in colitis
Faecalibacterium prausnitzii plays a crucial role in ulcerative colitis (UC) remission, but its action mechanism is unknown. Here, we aimed to explore the potential mechanisms focusing on the interaction of F. prausnitzii with host immune response and its potential modulation on gut microbiome. RNA-seq analysis together with 16S rRNA sequencing and metabolomics were performed in a dextran sodium sulfate (DSS)-induced colitis mouse model followed by F. prausnitzii gavage. To present evidence of sIgA involved in the anti-inflammatory effects of F. prausnitzii, we further applied immunoglobulin A (IgA) knockout mice and secretory IgA (sIgA) depletion mouse models using polymeric immunoglobulin receptor (pIgR) neutralizing antibody. Colonic immune cells were characterized by flow cytometry. The fecal relative abundance of F. prausnitzii, inecalcitol, and colonic IgA expression were assessed in UC patients. F. prausnitzii markedly ameliorated colitis by alleviating intestinal inflammation and barrier dysfunction, with significantly decreased abundance of pro-inflammatory taxa (Enterococcus, Desulfovibrio, Escherichia-Shigella, and Enterorhabdus) and increased abundance of Lachnospiraceae NK4A136_group. Functions related to intestinal immune network for IgA production pathway were up-regulated shown by transcriptomics and KEGG pathway analysis. Increased expression of IgA production associated genes including MHCII-related genes, Aicda, and Tnfrsfl3c were verified, accompanied by up-regulated colonic IgA and pIgR. The IgA knockout mice and sIgA depletion model weakened the anti-inflammation and microbiota-modulation effects of F. prausnitzii, which was further proved by fecal microbiota transplantation (FMT). The shift profile of fecal metabolites after F. prausnitzii supplement was characterized by increased production of inecalcitol, which may account for the enhanced IgA response. In a cohort of UC patients, the relative abundance of F. prausnitzii was decreased and positively correlated with colonic IgA expression and negatively correlated with disease severity. F. prausnitzii effectively alleviated colonic inflammation and modulated dysbiosis via enhancing colonic IgA response, thus showing promise as a UC treatment.
- Open Access
- 5 June 2025
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 139 (14) , 2210-2212
SRA1, APOA5, and AIFM2 identified as novel genetic risk factors in recurrent hypertriglyceridemia-associated acute pancreatitis by whole-exome sequencing
- 5 June 2025
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 139 (14) , 2210-2212
Open AccessSRA1, APOA5, and AIFM2 identified as novel genetic risk factors in recurrent hypertriglyceridemia-associated acute pancreatitis by whole-exome sequencing